Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Atrix Laboratories, Inc.
Patent extends Eligard product protection to 2018
July 30th, 2003
Atrix Laboratories, Inc., (ATRX) announced that the U.S. Patent Office issued Patent No. 6,565,874 on May 20, 2003, which effectively extends patent protection for the prostate cancer products franchise, Eligard (leuprolide acetate for injectable suspension), for the palliative treatment of advanced prostate cancer, to 2018. Sanofi-Synthelabo, Inc., is the U.S. marketing partner for the Eligard prostate cancer products. "Eligard was previously protected under more general Atrigel system patents covering formulation of Atrigel with a 'biologically active' agent," said Dr. Charles P. Cox, senior vice president of corporate development. "This new patent...
Source: Biotech Week (2003-07-30)
|
